H.C. Wainwright raised the firm’s price target on Denali Therapeutics (DNLI) to $42 from $32 and keeps a Buy rating on the shares after the FDA granted accelerated approval for Avlayah for the treatment of neurologic manifestations of Hunter syndrome. The firm says the label breadth exceeds its base case assumptions.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target raised to $42 from $40 at Morgan Stanley
- Denali Therapeutics price target raised to $31 from $29 at BofA
- Denali Therapeutics price target raised to $41 from $34 at Stifel
- Denali Therapeutics price target raised to $32 from $29 at Baird
- Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target